Author | Sonja Althammer, PhD | OncLive

Author | Sonja Althammer, PhD


Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

November 17, 2016


​Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.